作为全球肿瘤领域顶级学术盛会，2026 年欧洲肿瘤内科学会年会（ESMO Congress 2026）将于当地时间 10 月 23 日至 27 日于西班牙马德里启幕。7 月 17 日，ESMO 官方已正式公布本届会议中常规摘要及讲者信息。【肿瘤资讯】特梳理 Proffered Paper Session、Rapid Oral Session 中中枢神经系统肿瘤相关专场临床研究，带您一文速览前沿资讯。
Proffered paper: CNS tumours
摘要号：690O
标题：Final results of the TUXEDO-3 phase II trial of patritumab deruxtecan (HER3-DXd) in active brain metastases (BMs) and leptomeningeal disease (LMD)
中文标题：TUXEDO-3 II期试验最终结果：patritumab deruxtecan（HER3-DXd）在活动性脑转移及软脑膜疾病中的应用
讲者：Matthias Preusser (Vienna, Austria)
摘要号691O
标题：A First in Human Phase 1 Study of Intrathecal Peptide-Pulsed Dendritic Cells for HER2+ and Triple Negative Breast Cancer Leptomeningeal Disease
中文标题：鞘内注射肽脉冲树突状细胞治疗HER2阳性及三阴性乳腺癌软脑膜疾病的首次人体1期研究
讲者：Peter Forsyth (Tampa, United States of America)
摘要号：692O
标题：Randomized phase II trial investigating addition of trotabresib (CC-90010) to radiotherapy and temozolomide in patients with newly diagnosed IDH wild-type glioblastoma
中文标题：一项评估在放疗和替莫唑胺基础上联合trotabresib（CC-90010）用于新诊断IDH野生型胶质母细胞瘤患者的随机II期试验
讲者：Angelo Dipasquale (Rozzano, Italy)
摘要号：693O
标题：First-in-humanTERT-targeting nanoaggregate vaccine shows safety and induces intratumoral immune responses in newly diagnosed glioblastoma
中文标题：首次人体靶向TERT的纳米聚集体疫苗在新诊断胶质母细胞瘤中显示出安全性，并可诱导瘤内免疫反应
讲者：Antoine F. Carpentier (Paris, France)
摘要号：694O
标题：Clinical benefit of matched targeted therapy in CNS tumors: results from 349 patients in IMPRESS-Norway
中文标题：中枢神经系统肿瘤中匹配靶向治疗的临床获益：来自IMPRESS-Norway研究中349例患者的结果
讲者：Pitt Niehusmann (Oslo, Norway)
Rapid oral: CNS tumours
摘要号：695RO
标题：Early predictors of vorasidenib efficacy in IDH-mutant grade 2 glioma: a prospective study integrating volumetric MRI, amino acid PET, plasma D-2-hydroxyglutarate, and seizure outcome
中文标题：伏昔尼布在IDH突变型2级胶质瘤中疗效的早期预测指标：基于容积MRI、氨基酸PET、血浆D-2-羟基戊二酸及癫痫转归的前瞻性研究
讲者：Francesco Bruno (Turin, Italy)
摘要号：696RO
标题：Non-invasive finger sweat-based response monitoring of vorasidenib treatment in patients with IDH-mutant glioma
中文标题：利用手指汗液进行无创监测以评估伏昔尼布在IDH突变胶质瘤患者中的治疗反应
讲者：Vincent Sunder-Plassmann (Vienna, Austria)
摘要号：697RO
标题：The international validation of a liquid biopsy platform for the early detection of brain tumours
中文标题：用于早期检测脑肿瘤的液体活检平台的国际验证
讲者：Paul Brennan (Edinburgh, United Kingdom)摘要号：698RO
标题：A phase Ib Clinical Trial on Combined (Neo-)Adjuvant Intravenous (IV) Plus Intracranial Administration of Ipilimumab (IPI) and Nivolumab (NIVO) in Resectable Recurrent Glioblastoma (rGBM): NEO-GLITIPNI
中文标题：伊匹木单抗联合纳武利尤单抗（新）辅助静脉及颅内给药治疗可切除复发性胶质母细胞瘤的1b期临床试验：NEO-GLITIPNI
讲者：Iris Dirven (Jette, Belgium)
摘要号：699RO标题：Dose escalation of Debio 0123 (zedoresertib) plus temozolomide (TMZ) in patients (pts) with recurrent or progressive glioblastoma (GBM)
中文标题：Debio 0123（zedoresertib）联合替莫唑胺治疗复发性或进展性胶质母细胞瘤患者的剂量递增研究讲者：Maria Vieito (Barcelona, Spain)
摘要号：700RO标题：Intracerebral (iCer) ipilimumab (IPI) and nivolumab (NIVO), with or without autologous CD1c(BDCA-1)+/CD141(BDCA-3)+ myeloid dendritic cells (myDC) in patients with resectable recurrent high-grade glioma (rHGG), 5-year survival outcome
中文标题：颅内（iCer）注射伊匹木单抗（IPI）和纳武利尤单抗（NIVO），联合或不联合自体CD1c（BDCA-1）⁺/CD141（BDCA-3）⁺髓样树突状细胞（myDC），治疗可切除复发性高级别胶质瘤（rHGG）患者的5年生存结局
讲者：Cleo Bertels (Jette, Belgium)摘要号：701RO
标题：Clinical Activity and Safety of Novel Brain-Penetrant BRAF Inhibitor HSK42360 in BRAF V600-Mutated Gliomas: Initial Results from a Phase 1 Study
中文标题：新型脑渗透性BRAF抑制剂HSK42360在BRAF V600突变型胶质瘤中的临床活性与安全性：一项1期研究的初步结果
讲者：李文斌 (北京天坛医院)
摘要号：702RO
标题：Immune checkpoint blockade for patients with leptomeningeal metastases from non-small cell lung cancer
中文标题：免疫检查点抑制剂在非小细胞肺癌软脑膜转移患者中的应用
讲者：郑媚美 (广东省人民医院)
摘要号：703RO
标题：Inflammatory and epigenetic signatures in progressive brain metastases after cranial radiotherapy
中文标题：颅脑放疗后进展性脑转移中的炎症和表观遗传学特征
讲者：Ariane Steindl (Vienna, Austria)（官网持续更新中，如有疏漏，欢迎补充）
排版编辑：肿瘤资讯-云初
苏公网安备32059002004080号
